Pre ‐anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Authors: Source Type: research

Related Links:

Conditions:   Relapsed AML;   T(8;21);   C-KIT Mutation Intervention:   Drug: Dasatinib Sponsor:   Institute of Hematology & Blood Diseases Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia, Published online: 18 June 2018; doi:10.1038/s41417-018-0027-0Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Authors: Cao H, Zhao X, Lu S, Wang Z Abstract The aim of the current study was to measure the expression of acetyl-N-Ser-Asp-Lys-Pro (ACSDKP) in patients with acute myeloid leukemia (AML) and the effect of prolyl oligopeptidase inhibitor (POPi) on the bone marrow stromal cells of these patients. Serum and bone marrow stromal cell samples were collected from 33 patients with AML admitted to Wuxi Second People's Hospital, Nanjing Medical University between September 2011 and August 2016. ACSDKP levels were measured using a highly specific competitive enzyme immunoassay (EIA). Bone marrow stromal cells were treated wi...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
CONCLUSIONS: Interactions between leukemia cells and the bone marrow niche influence hematopoiesis, leukemogenesis, and chemotherapy resistance in AML and require ongoing study. Understanding the mechanisms that underlie these interactions will help identify rational niche-targeting therapies to improve treatment outcomes in AML patients. PMID: 29902132 [PubMed - as supplied by publisher]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Acute myeloid leukemia is a highly aggressive malignancy with a high morbidity rate, for which an accurate and rapid diagnostic is essential. Acute myeloid leukemia manifestations frequently include oral abnormalities. Still, there is a limited number of studies reporting the incidence of oral manifestations in acute leukemia, the prevalence of periodontal status and periodontal parameters in these patients. Our aim was to emphasize the importance of early recognition by the dental practitioners of oral cavity manifestations as signs of acute myeloid leukemia, so that prompt referral to the hematologists is being done, and...
Source: Medical Hypotheses - Category: Biomedical Science Authors: Source Type: research
Acute myeloid leukemia (AML) is a heterogeneous hematologic neoplasm characterized by clonal proliferation of myeloid precursor cells in the peripheral blood, bone marrow, and/or other tissues [1]. There are an estimated 21,000 new cases of AML diagnosed annually in the United States (US), with the incidence steadily increasing at about 5% per year [2,3]. AML is generally a disease affecting elderly patients, with a median age at diagnosis of 69 years [4]. The overall prognosis for AML is poor, with less than 30% of patients surviving 5 years from diagnosis; however, outcomes vary according to multiple prognostic factors, ...
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
Authors: Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, Meshinchi S, He J Abstract Large scale comprehensive genomic profiling (CGP) has led to an improved understanding of oncogenic mutations in acute myeloid leukemia (AML), as well as identification of alterations that can serve as targets for potential therapeutic intervention. We sought to gain insight into age-associated variants in AML through comparison of extensive DNA and RNA-based GP results from pediatric and adult AML. Seque...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients. Mol Med Rep. 2018 Jun 06;: Authors: Wang F, Tian X, Zhou J, Wang G, Yu W, Li Z, Fan Z, Zhang W, Liang A Abstract Long non-coding RNAs (lncRNAs) are transcripts characterized by>200 nucleotides, without validated protein production. Previous studies have demonstrated that certain lncRNAs have a critical role in the initiation and development of acute myeloid leukemia (AML). In the present study, the subtype‑specific lncRNAs in AML was identified. Following the exclusion of the subtype‑specific lncRNAs, the ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Conditions:   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: FMS Inhibitor JNJ-40346527;   Other: Pharmacokinetic Study Sponsor:   OHSU Knight Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder Intervention:   Drug: Ruxolitinib Sponsor:   Seoul National University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia